Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma - Wikidata - awgldk - TriplyDB

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

http://www.wikidata.org/entity/Q36206430

about

MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib The tumor microenvironment shapes hallmarks of mature B-cell malignancies.A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance Tyrosine phosphorylation of WIP releases bound WASP and impairs podosome assembly in macrophages Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor New strategies in the treatment of multiple myeloma.Novel therapeutic targets in myeloma bone disease.Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.Bone disease in multiple myeloma: pathophysiology and management.A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors.Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice Sotatercept in patients with osteolytic lesions of multiple myeloma.Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression.Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies Novel Bruton's tyrosine kinase inhibitors currently in development.HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease Bone marrow microenvironment in cancer patients: immunological aspects and clinical implications.Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.Overcoming bortezomib resistance in multiple myeloma.

P2860

Q26765477-ACBE2515-F3F2-4549-B238-29B2B73C0AEE Q26785497-54923F04-F962-4C70-A534-668B23C45B6A Q26822700-37B51730-8E92-461E-8BDE-C88FBB9CCF23 Q27025812-E288D1FB-D237-4E0A-A482-7608B721ED80 Q27687567-439B07D4-3E07-450B-84DB-67CB25630352 Q28395203-08B015AB-E6B2-44EF-9901-1BA864075E14 Q30615575-E1AB0DE6-889C-4631-B9E9-02BF1B0C2BEF Q30661625-9AF17F4B-44FB-4E0A-B26D-461065224B00 Q33958520-E45344E0-0D27-4833-8122-DF9BD9005939 Q34025065-313A6CF9-820B-426E-81C2-66B79D95E198 Q34039406-EDE782EB-254C-4CF5-8156-E9AB9CE7ABD1 Q34042250-43817A7E-7631-4649-A162-E25BBCE961AB Q34042407-4E115691-E205-42D6-B8F1-5F99CC7DE95B Q34045789-1A600302-F67F-46BA-BBB5-B0A68A486655 Q34067085-C2CFB38A-1881-4A41-B67D-5C1023E3BD86 Q34354339-1F4C2B5D-E092-4684-A562-DEE6A1B4508C Q34448984-3D3D1D30-17C9-4CA5-AC35-CCCBB5F97331 Q34722000-405D1C90-35C4-40A0-8C44-206AFAA3B7B4 Q34773850-0DD2897A-80C1-49CE-B820-3DBDFA56D833 Q34861202-4D0CC90C-2C3E-4C81-AA0C-1592980B8599 Q35035011-B0FFD2FA-470E-4064-966A-C01F23039CA1 Q35067806-C754E541-B544-4ADA-ADF6-4A4518CC3DB5 Q35260732-A2B6D6B8-C28D-4938-B6CF-F4E5A446CA95 Q35889653-87AC8D07-3873-4728-820E-04A1264F4D74 Q35979385-77F61728-1E59-4201-83D4-26C7F896D64E Q36020943-7C2FB6A8-20D8-490E-898B-EE47A6C88C1B Q36183770-01F5FEA7-753C-47B8-84A9-51B3EE80F8E3 Q36334833-A0F1031D-D16F-469D-9C9A-1259BA415BE6 Q36337598-CCDBC1B6-77CB-4E0E-B649-FC462AB6BDEA Q36602853-FAE05BF9-FE63-4CD3-9F78-31D1A9FC3B55 Q36673755-E731E0CE-EB94-47C8-B749-DF7ACBC3132F Q36810546-59896B55-97A6-45FC-82DD-8998421ABD2F Q37035836-98055100-4E45-443C-9AC0-8792F431CC4D Q37445828-E778EB15-3B73-4E6F-8B13-BC52FEA99EEB Q37552008-EF8B27CE-BE43-4998-8ACA-81B8C0D2637B Q37678085-CFD9D12A-BE6A-4BDD-85F7-8EC76E12428A Q38053396-E63B0AEC-66CF-45FB-A1BE-118A734F4493 Q38083077-DF550186-DE33-4D8E-8564-BC984D217D54 Q38171390-8C6634BC-B1C1-4512-B3D5-D89496733BA9 Q38238610-D31837F0-A8B3-40D3-87E9-2EC053A3A142

P2860

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

http://www.wikidata.org/entity/Q36206430

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Bruton tyrosine kinase inhibit ...... nvironment in multiple myeloma

@ast

Bruton tyrosine kinase inhibit ...... nvironment in multiple myeloma

@en

type

label

Bruton tyrosine kinase inhibit ...... nvironment in multiple myeloma

@ast

Bruton tyrosine kinase inhibit ...... nvironment in multiple myeloma

@en

prefLabel

Bruton tyrosine kinase inhibit ...... nvironment in multiple myeloma

@ast

Bruton tyrosine kinase inhibit ...... nvironment in multiple myeloma

@en

P1433

Q36206430-11118283-0355-485E-A1FB-44D5A4EDCBA2

P1476

Q36206430-4EFD2EC2-3F29-4962-9A67-E4BBC082CB3F

P2093

Q36206430-046C9C8F-8BBD-4B11-92F7-3B65C132C312

Q36206430-074D0A7F-E652-4B93-8305-DE8A52A63C9D

Q36206430-31B04F78-CE2C-41BE-AEDF-98277D852F73

Q36206430-36E7ADDA-C05F-4853-876C-09B53DE731D1

Q36206430-4436610B-BC2B-46C3-9A58-4C5CB03CF0D7

Q36206430-4A72E863-FE99-4CE2-8DD4-F67B531B6819

Q36206430-538EBB43-DE5E-4D53-87D1-00D48EEA52C5

Q36206430-65241DEF-222E-4D4D-8B25-97C7DD1A44C7

Q36206430-71C7200D-6EB0-48B1-994C-B032CF47FB9E

Q36206430-9462878B-044F-4286-AD96-F4CAC0D4C255

P2860

Q36206430-03074EA2-94A3-49E3-9D96-5D57007EECCC

Q36206430-0579DC4D-CDB2-4E2A-B2B0-55CA66FEA75F

Q36206430-0897DB86-F39F-4E9C-9DAE-E10899387A32

Q36206430-097EA9DE-91DC-4F5F-8EA6-E43D039483D6

Q36206430-118B26E7-89A6-4883-8266-C43CF91BB4F0

Q36206430-129AF129-B253-4569-A766-323B129EDD6A

Q36206430-13459D8A-99CF-4939-9029-F7692CDA3165

Q36206430-16D6341F-D0AB-4392-A84D-8CD1A44B8EC0

Q36206430-1988AECD-5A9F-42BA-A24C-C97D06F92E8A

Q36206430-234105C9-C789-4211-BECD-010B01074DE2

P304

Q36206430-BEDD0F86-3D0B-43BA-9202-EF18B2CBD12A

P31

Q36206430-0A270B72-1331-4FC7-9364-18B41D11B44C

P356

Q36206430-786CD696-A5F6-4CDB-8828-8707C496F235

P407

Q36206430-BB32FFD4-5CC2-466C-BD39-93F2A050ECD0

P433

Q36206430-CE95E583-2225-4EFE-97CD-C0B13EBB6E09

P478

Q36206430-A4D36129-9667-4824-AF46-A1D2125351AA

P50

Q36206430-47549746-A4D8-4A62-84A6-D1A8925A746C

Q36206430-62F27CFE-05FB-42A0-96D6-869B0EBF1597

Q36206430-71AF2783-6BDD-4084-918F-0D03AECFEBBB

Q36206430-9AF25CC3-FEEA-4418-8A2C-2C6F62F1B675

Q36206430-AEB068DC-11CD-441B-A5F9-16DE87949E00

P577

Q36206430-2D17A8C6-929E-47ED-8E5A-9BE5E8BA3B01

P5875

Q36206430-83B88132-F397-474B-B259-34D7A9B6BCFA

P698

Q36206430-38C02345-FF08-4139-A6C7-4D85F0EF8AE4

P921

Q36206430-37ABAF93-B142-4AC7-A96B-FB67C5B34AD9

P932

Q36206430-B3CF5637-5376-4BF7-8505-30111A101F10

P356

BLOOD-2011-12-396853

P1433

P1476

Bruton tyrosine kinase inhibit ...... nvironment in multiple myeloma

@en

P2093

Antonia Cagnetta

http://www.w3.org/2001/XMLSchema#string

Betty Y Chang

http://www.w3.org/2001/XMLSchema#string

Chirag Acharya

http://www.w3.org/2001/XMLSchema#string

Daniel R Carrasco

http://www.w3.org/2001/XMLSchema#string

Guang Yang

http://www.w3.org/2001/XMLSchema#string

Jian-Jun Zhao

http://www.w3.org/2001/XMLSchema#string

Jianhong Lin

http://www.w3.org/2001/XMLSchema#string

Joseph J Buggy

http://www.w3.org/2001/XMLSchema#string

Laurence Elias

http://www.w3.org/2001/XMLSchema#string

Mariateresa Fulciniti

http://www.w3.org/2001/XMLSchema#string

P2860

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

Characterization of clonogenic multiple myeloma cells

Giant osteoclast formation and long-term oral bisphosphonate therapy

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature

Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms

Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth

Signaling network of the Btk family kinases.

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

APRIL is overexpressed in cancer: link with tumor progression

P304

1877-1887

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-12-396853

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Paul G Richardson

P577

2012-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225293665

http://www.w3.org/2001/XMLSchema#string

P698

22689860

http://www.w3.org/2001/XMLSchema#string

P921

P932

3433091

http://www.w3.org/2001/XMLSchema#string